Your browser doesn't support javascript.
loading
Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19.
Foo, Hong; Phan, Fiona; Bagatella, Melissa; Petrovski, Irene; Nagendra, Vana; Acharya, Priya; Levy, Miriam; Prakoso, Emilia.
Affiliation
  • Foo H; Department of Microbiology and Infectious Diseases, NSW Health Pathology - Liverpool, Sydney, Australia. hong.foo@health.nsw.gov.au.
  • Phan F; Department of Gastroenterology, Liverpool Hospital, Sydney, Australia.
  • Bagatella M; Department of Gastroenterology, Liverpool Hospital, Sydney, Australia.
  • Petrovski I; Department of Gastroenterology, Campbelltown Hospital, Sydney, Australia.
  • Nagendra V; Department of Microbiology and Infectious Diseases, NSW Health Pathology - Liverpool, Sydney, Australia.
  • Acharya P; Department of Gastroenterology, Campbelltown Hospital, Sydney, Australia.
  • Levy M; Department of Gastroenterology, Liverpool Hospital, Sydney, Australia.
  • Prakoso E; University of New South Wales, Sydney, Australia.
Eur J Clin Microbiol Infect Dis ; 42(6): 799-801, 2023 06.
Article in En | MEDLINE | ID: mdl-37084117
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: COVID-19 / Hepatitis B Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: COVID-19 / Hepatitis B Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Year: 2023 Type: Article